MyFinsight
Home
Blog
About
Recorlev
$56,780,000
(80.57%↑ Y/Y)
Gvoke
$22,549,000
(-3.91%↓ Y/Y)
Keveyis
$11,675,000
(1.65%↑ Y/Y)
Comprehensive loss
-$31,087,000
(-1513.23%↓ Y/Y)
Foreign currency
translation adjustments
$14,000
(1300.00%↑ Y/Y)
Product
$91,004,000
(34.41%↑ Y/Y)
Royalty Contract And
Other Revenue
$1,096,000
(-71.39%↓ Y/Y)
Net loss
-$31,101,000
(-1513.12%↓ Y/Y)
Product revenue, net
$92,100,000
(28.74%↑ Y/Y)
Net loss before
income taxes
-$31,101,000
(-1513.12%↓ Y/Y)
Income from operations
$5,173,000
(15.42%↑ Y/Y)
Total costs and
expenses
$86,927,000
(29.63%↑ Y/Y)
Total other expense
-$36,274,000
(-465.90%↓ Y/Y)
Interest and other income
$1,455,000
(53.48%↑ Y/Y)
Selling, general and
administrative
$61,035,000
(37.49%↑ Y/Y)
Cost of goods sold
$12,512,000
(5.16%↑ Y/Y)
Research and development
$10,669,000
(32.45%↑ Y/Y)
Amortization of intangible
assets
$2,711,000
(0.00%↑ Y/Y)
Loss on debt
extinguishment, net
-$30,782,000
Interest expense
$6,947,000
(-5.59%↓ Y/Y)
Back
Back
Income Statement
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)
source: myfinsight.com